ABBV
Stock Details
ABBV is AbbVie Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 151.49$. Average daily volumn in 3 months 6.33M. Market cap 276.24B
Stock symbol : ABBV. Exchange : NYSE. Currency : USD Lastest price : 156.12$. Total volume : 4.32M. Market state PRE Click reload if you want to check the lastest price on market!!!
AbbVie Inc. (ABBV)
Last Price
156.12$Change
1.90Volume
4.32M
| Previous Close | 154.22 |
| Open | 154.52 |
| Day Range | 154.46-156.34 |
| Bid | 155.18 x 900 |
| Ask | 157.00 x 1k |
| Volume | 4.32M |
| Average Volume | 6.33M |
| Market Cap | 276.24B |
| Beta | 0.59 |
| 52 Week Range | 134.09-175.91 |
| Trailing P/E | 23.51 |
| Foward P/E | 14.04 |
| Dividend (Yield %) | 3.79% |
| Ex-Dividend Date | 2023-04-13 |
Financial Details
Organization
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the tr... eatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Market Cap:
276.24BRevenue:
58.05BTotal Assets:
138.81BTotal Cash:
9.2B
News about "AbbVie Inc."
AbbVie Inc. (ABBV) Stock Price and Analyst Predictions
Source from : newsheater - 10 hours ago
AbbVie Inc. (NYSE: ABBV) has a price-to-earnings ratio that is above its average at 23.55x. and a 36-month beta value of 0.55. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 0 ...See details»
Boasting A 69% Return On Equity, Is AbbVie Inc. (NYSE:ABBV) A Top Quality Stock?
Source from : YAHOO!Finance - 2 days ago
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article ...See details»
AbbVie Inc. stock outperforms market on strong trading day
Source from : MarketWatch - 5 days ago
Shares of AbbVie Inc. inched 0.14% higher to $154.06 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the ...See details»
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Source from : Zacks.com on MSN - 11 days ago
AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...See details»
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
Source from : MSN - 1 month ago
AbbVie is expected to post earnings of $2.58 per share for the current quarter, representing a year-over-year change of -18.4%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.8%.See details»
AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 81% Above Its Share Price
Source from : YAHOO!Finance - 7 days ago
Key Insights Using the 2 Stage Free Cash Flow to Equity, AbbVie fair value estimate is US$275 AbbVie is estimated to ...See details»
AbbVie Inc. (ABBV) Shares Up Despite Recent Market Volatility
Source from : newsheater - 27 days ago
AbbVie Inc. (NYSE: ABBV)’s stock price has increased by 1.60 compared to its previous closing price of 147.35. Despite this, the company has experienced a -4.07% fall in its stock price over the last ...See details»
AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results
Source from : Stockhouse - 1 month ago
fair value step-up for inventory related to the Allergan acquisition partially offset by a recovery of certain Allergan acquisition-related regulatory fees. Other primarily includes the purchase of ...See details»
AbbVie Has a Mixed Outlook After Mixed Earnings
Source from : Nasdaq - 1 month ago
AbbVie Inc. (NYSE: ABBV) stock is back to where it started after the day after posting a mixed fourth-quarter earnings report. The company delivered a slight beat on expected earnings but came in ...See details»
Abbvie Inc
Source from : Reuters - 1 month ago
Marketscategory Wall St dips as Treasury yields rise after auction, article with video February 10, 2023 Businesscategory AbbVie sees 37% drop in Humira sales this year as biosimilars hit U.S ...See details»
AbbVie Inc. 2022 Q4 - Results - Earnings Call Presentation
Source from : Seeking Alpha - 28 days ago
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site ...See details»
AbbVie Declares Quarterly Dividend
Source from : Morningstar - 1 month ago
NORTH CHICAGO, Ill., Feb. 16, 2023 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.48 per share. The cash dividend is payable ...See details»
Morgan Stanley Sticks to Their Buy Rating for AbbVie (ABBV)
Source from : Business Insider - 13 days ago
See which 3 stocks are most likely to make moves following their insider activities. AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology ...See details»
ABBV.N - | Stock Price & Latest News | Reuters
Source from : Reuters - 3 month ago
AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and ...See details»